Friday 17 April 2026

The Pharmaletter

Axxam

A privately held contract research organization (CRO) specializing in early-stage drug discovery across the life sciences sector.

Company Overview

Want to Update your Company's Profile?


Latest Axxam News

Axxam and Molecular Health take AI-biology blend to early drug discovery
9 June 2025
Axxam signs up for CNS collaboration with French pharma major
5 September 2017
Grünenthal to capitalize on Axxam's drug discovery platform
8 March 2016
More Axxam news >


Today's issue

Ryght AI introduces world’s first, free, AI-powered clinical trial site search engine
Pharmaceutical
Ryght AI introduces world’s first, free, AI-powered clinical trial site search engine
17 April 2026
Biotechnology
MeiraGTx reacquires bota-vec rights and prices public offering
16 April 2026
Biotechnology
Alethio Therapeutics unveils ATX-011, a breakthrough for treating essential thrombocythemia
16 April 2026
Pharmaceutical
ICER white paper on accelerated approval pathway for Rx drugs
16 April 2026
Pharmaceutical
Daiichi Sankyo transfers healthcare unit to Suntory
16 April 2026
Biosimilars
Mochida inks agreement for a biosimilar of follitropin alfa
16 April 2026
Biotechnology
Terremoto investors see ‘full potential of selective AKT1 inhibition’
16 April 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze